Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in Active Psoriatic Arthritis with Inadequate Response to Anti-TNF
NCT03796858Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2019
- Primary completion
- Nov 2020
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Guselkumab with Placebo -> Guselkumab (2 arms). Primary endpoint: American College of Rheumatology 20 Response at Week 24. Started Mar 2019; status: completed.
02
Drugs
guselkumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT03796858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03796858.